Clinical Trial Update: ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection [Phase 3]

View source ↗

Summary

Phase 3 open-label trial of SER-109 for recurrent Clostridioides difficile infection has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• SER-109

Snippet

Sponsor: Seres Therapeutics, Inc. | Conditions: Clostridioides Difficile Infection | Phase 3 | Status: COMPLETED | Results posted: 2023-03-31